Food safety regulator takes legal action against Nestlé India for alleged nutrition rules violation
The Food Safety and Standards Authority of India (FSSAI) has initiated legal action against Nestlé India after tests revealed that a sample of one of its baby food products, a 'follow-up formula' for infants, was sub-standard due to insufficient biotin levels. Additionally, FSSAI flagged two other products, NAN Excella Pro Stage 1 and Lactogen Pro 1, for allegedly misleading claims related to ingredients like '5 HMOs' and whey protein, which violate the 2020 Foods for Infant Nutrition Regulations and the 1992 Infant Milk Substitutes Act. Nestlé India stated that its products are fully compliant with regulations and that the claims on the labels are factual and supported by scientific evidence. The company emphasized that these products were approved by an expert committee of the regulator. Following the announcement, Nestlé India's stock price initially dropped but partially recovered by the end of trading. This action comes amid increased scrutiny by Indian food regulators on issues such as food adulteration and misleading advertising.
Nestle India faces legal action as the Food Safety and Standards Authority of India (FSSAI) alleges violations in the quality and promotion of three baby food products. On Friday, the regulator announced it had taken legal steps against the company over findings related to a follow-up formula and two other infant nutrition products. A sample of the follow-up formula was found to be substandard with respect to biotin content during laboratory analysis. The FSSAI stated that a reanalysis confirmed the sample did not meet the prescribed biotin requirements under the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020. Nestle India responded by asserting that its products are fully compliant with all applicable regulations and that it continues to collaborate with the FSSAI. The company’s shares initially dropped nearly 3% following the regulatory action but recovered to close almost flat. The spokesperson for Nestle India mentioned that the two products cited for promotional violations, NAN Excella Pro Stage 1 and Lactogen Pro 1, had their labels approved by the regulator’s expert committee. The company reiterated that the statements on the labels are factual and backed by scientific literature. The FSSAI flagged the promotional claims of these two products as contravening Regulation 4(2) of the 2020 Foods for Infant Nutrition Regulations and Section 3 of the 1992 Infant Milk Substitutes Act. These regulations prohibit promotional activities aimed at increasing the saleability of infant foods and ban their advertising. The regulator noted that the NAN Excella Pro Stage 1 claimed to contain “5 HMOs” and whey protein, while the Lactogen Pro 1 made a claim about whey protein being “easy to digest.” The FSSAI stated that these claims were deemed misleading. This legal action comes as part of a broader crackdown by Indian food regulators on food adulteration and misleading advertisements. The FSSAI has recently conducted several raids and inspections, leading to the issuance of warnings and shutdowns of some businesses. The agency has also flagged over 160 misleading claims in the past, though many remain unresolved. Nestle India’s milk and nutrition products, including infant formulas and baby foods, constituted the largest revenue category for the company in the fiscal year ending March 2026, contributing approximately $2.4 billion in sales. This segment accounts for a third of the company’s total product sales. The company has previously faced regulatory scrutiny, notably in 2015 when its Maggi noodles were temporarily banned due to concerns over lead levels and labeling inaccuracies. After subsequent testing, the product was allowed back onto store shelves. The FSSAI has initiated three separate adjudication cases against Nestle India over the three affected products. While the regulator did not mention any immediate plans for a product recall, the legal proceedings could have implications for the company’s operations and reputation. The ongoing regulatory actions highlight the growing emphasis on stringent compliance and transparency in the food sector, particularly concerning infant nutrition products.
Go to the primary sources (2)
The official sources this coverage is built on. Read them directly to bypass framing.
The Indian Food Safety and Standards Authority (FSSAI) has initiated legal action against Nestlé India over three baby food products. A sample of a follow-up formula was found to have insufficient biotin content, violating quality standards. Additionally, two other products, NAN Excella Pro Stage 1 and Lactogen Pro 1, were flagged for promotional violations, breaching regulations that restrict advertising of infant nutrition products. Nestlé maintains its products comply with all regulations and asserts that the promotional claims are factually accurate and backed by scientific evidence. The company's shares initially dropped but recovered slightly. This follows a previous controversy in 2015 involving its Maggi noodles.
Bias read (Center): The article presents factual findings from the FSSAI and quotes both the regulator and Nestlé's spokesperson without overtly favoring either side. While the issue involves regulatory enforcement and corporate compliance, the framing remains balanced, focusing on the technical aspects of the product,
Why factuality (90): This article presents a clear and detailed account of the FSSAI's legal action against Nestlé India, citing specific regulations and providing information on the reanalysis process. It includes direct quotes from the FSSAI and mentions the impact on Nestlé's stock, which adds contextual depth. It al
Why objectivity (85): The article maintains a balanced tone, reporting both the regulator's findings and Nestlé's response. There is minimal bias, though the mention of share price drop might subtly suggest market reaction rather than an objective report.
The Food Safety and Standards Authority of India (FSSAI) has initiated legal action against Nestlé India after tests revealed that a sample of one of its baby food products, a 'follow-up formula' for infants, was sub-standard due to insufficient biotin levels. Additionally, FSSAI flagged two other products, NAN Excella Pro Stage 1 and Lactogen Pro 1, for allegedly misleading claims related to ingredients like '5 HMOs' and whey protein, which violate the 2020 Foods for Infant Nutrition Regulations and the 1992 Infant Milk Substitutes Act. Nestlé India stated that its products are fully compliant with regulations and that the claims on the labels are factual and supported by scientific evidence. The company emphasized that these products were approved by an expert committee of the regulator. Following the announcement, Nestlé India's stock price initially dropped but partially recovered by the end of trading. This action comes amid increased scrutiny by Indian food regulators on issues such as food adulteration and misleading advertising.
Bias read (Center): The article presents both the regulatory actions taken by the Food Safety and Standards Authority of India (FSSAI) and Nestlé India's response, providing balanced perspectives without overtly favoring either side. There is no clear indication of biased language, one-sided sourcing, or omission of a
Why factuality (85): The article accurately reports that the FSSAI took legal action against Nestlé India following a substandard sample test result and allegations of misleading claims. It references specific regulations and provides details about the products involved. While it does not include direct quotes from the
Why objectivity (80): The tone remains neutral, presenting both sides of the issue – the regulator's actions and Nestlé's defense. However, there is slight editorializing in phrases like 'alleged' and 'flagged', which may imply some level of skepticism toward the company's claims.
Business StandardIndependent🔒CenterFactual: no official source document/info detectedObjective 70
The Food Safety and Standards Authority of India (FSSAI) has taken legal action against three Nestlé India food products, alleging violations of food safety regulations. The products in question were reportedly found to contain excessive levels of certain nutrients or contaminants, prompting regulatory scrutiny. This move by FSSAI highlights ongoing concerns over product compliance and consumer safety standards within the food industry. The legal proceedings may result in penalties or mandatory recalls for the affected products.
Bias read (Center): The article presents a factual report on regulatory action taken by a government agency against a corporate entity. There is no overt ideological framing or emphasis on specific political agendas. The focus remains on the regulatory process and compliance issues rather than partisan commentary.
Why factuality: no official source document/info detected
Why objectivity (70): The tone is neutral, but the lack of detail makes it difficult to assess objectivity. The brevity suggests a potential lack of depth, though no overt bias is evident.
Business StandardIndependent🔒CenterFactual: no official source document/info detectedObjective 70
The Food Safety and Standards Authority of India (FSSAI) has initiated legal action against Nestle India regarding certain infant food products. This move comes amid concerns over compliance with food safety regulations. The specific nature of the alleged violations has not been detailed in the available information. Such actions by regulatory authorities are typically aimed at ensuring adherence to quality and safety standards for consumer protection. The outcome of this legal proceeding could impact Nestle India's operations and reputation within the market.
Bias read (Center): The article reports on a regulatory action taken by a government authority against a private company. It does not exhibit clear bias toward either side, presenting the fact that legal action has been initiated without indicating approval or criticism of the decision. There is no evident framing that
Why factuality: no official source document/info detected
Why objectivity (70): The article is presented in a neutral manner, but due to its brevity and lack of detail, it is challenging to determine if it is objectively reporting the situation or simply summarizing it without context.
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.
India
